Business Segments · Interest Expense
Reportable Segment — Interest Expense
Eli Lilly Reportable Segment — Interest Expense increased by 84.9% to $332.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 36.1%, from $244.00M to $332.00M. Over 2 years (FY 2022 to FY 2024), Reportable Segment — Interest Expense shows an upward trend with a 53.4% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementSegment
CategoryLeverage
SignalLower is better
VolatilityStable
First reportedQ1 2022
Last reportedQ1 2026Apr 30, 2026
Rolls up toInterest Expense
How to read this metric
An increase may indicate higher debt levels or rising interest rates, potentially reducing segment profitability.
Detailed definition
Represents the cost incurred by the reportable segment for borrowed funds used to finance operations or capital projects...
Peer comparison
Standard across pharmaceutical peers, though often allocated based on internal capital charges.
Metric ID:
lly_segment_reportable_segment_interest_expenseHistorical Data
16 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $82.90M | $82.90M | $82.90M | $82.90M | $121.48M | $121.48M | $121.48M | $121.48M | $179.60M | $183.60M | $192.70M | $224.70M | $244.00M | $249.00M | $179.60M | $332.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +46.5% | +0.0% | +0.0% | +0.0% | +47.8% | +2.2% | +5.0% | +16.6% | +8.6% | +2.0% | -27.9% | +84.9% |
| YoY Change | — | — | — | — | +46.5% | +46.5% | +46.5% | +46.5% | +47.8% | +51.1% | +58.6% | +85.0% | +35.9% | +35.6% | -6.8% | +36.1% |
Range$82.90M – $332.00M
CAGR+44.8%
Avg YoY Growth+44.1%
Median YoY Growth+46.5%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's reportable segment — interest expense?
- Eli Lilly (LLY) reported reportable segment — interest expense of $332.00M in Q1 2026.
- How has Eli Lilly's reportable segment — interest expense changed year-over-year?
- Eli Lilly's reportable segment — interest expense increased by 36.1% year-over-year, from $244.00M to $332.00M.
- What is the long-term trend for Eli Lilly's reportable segment — interest expense?
- Over 2 years (2022 to 2024), Eli Lilly's reportable segment — interest expense has grown at a 53.4% compound annual growth rate (CAGR), from $331.60M to $780.60M.
- What does reportable segment — interest expense mean?
- The cost of interest paid on debt allocated to this specific business segment.